# Ajinomoto Althea, Inc. – FDA 483, Sep 20, 2023

Source: https://www.keypedia.com/records/483/ajinomoto-althea-inc/189c64ec-06f0-442c-9aaf-eb9ea48f6a0b

> FDA 483 for Ajinomoto Althea, Inc. on September 20, 2023. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Ajinomoto Althea, Inc.
- Inspection Date: 2023-09-20
- Product Type: drugs
- Office Name: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)
- Summary: Ajinomoto Althea, Inc. DBA Ajinomoto Bio-Pharma Services in San Diego, CA, was cited for significant deficiencies in microbial cross-contamination control and aseptic processing procedures. The inspection also found inadequate complaint investigations regarding particulate matter in finished drug products. These issues indicate a lack of robust quality control and adherence to sterile manufacturing practices.

## Related Documents

- [483 - 2025-05-09](https://www.keypedia.com/records/483/ajinomoto-althea-inc/460eb7ec-a1f2-489e-af6c-54a4f2adef31) — date: May 9, 2025
- [483 - 2023-02-09](https://www.keypedia.com/records/483/ajinomoto-althea-inc/580fc4cc-211e-489a-8466-337a0c433bff) — date: February 9, 2023
- [483 - 2023-01-16](https://www.keypedia.com/records/483/ajinomoto-althea-inc/31d386f5-e5ea-4cf9-b563-54c74ade61ef) — date: January 16, 2023
- [483 - 2021-05-25](https://www.keypedia.com/records/483/ajinomoto-althea-inc/a6e715c6-2e49-4494-ad26-7c9e6bc7e8c4) — date: May 25, 2021
- [EIR - 2019-12-20](https://www.keypedia.com/records/eir/ajinomoto-althea-inc/668193bb-da58-4599-829f-e401abd98ac9) — date: December 20, 2019

## Related Officers

- [Cai-huan Qin, PhD, CSO](https://www.keypedia.com/people/cai-huan-qin-phd-cso/63aa808d-74bd-491e-bdc4-c615539aab14)
- [Yi Wang, PhD, Staff Fellow](https://www.keypedia.com/people/yi-wang-phd-staff-fellow/5a38ae27-971d-41cc-be0f-7398c4228e7f)
- [investigator](https://www.keypedia.com/people/cassandra-l-abellard/e27aef11-adc6-449b-b7a8-f4c419549467)

Company: https://www.keypedia.com/companies/ajinomoto-althea-inc/75fb5ea8-b86f-45c1-946e-80c73765f544

Office: https://www.keypedia.com/offices/division-of-clinical-evidence-and-analysis-1-clinical-policy-and-quality/5f95da17-30bb-423f-b892-5ea041823fbd
